{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:47:47Z","timestamp":1778694467146,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006413","name":"Ariad Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.clml.2016.01.006","type":"journal-article","created":{"date-parts":[[2016,2,6]],"date-time":"2016-02-06T21:17:25Z","timestamp":1454793445000},"page":"275-285.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data"],"prefix":"10.1016","volume":"16","author":[{"given":"Kathleen","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dorer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1016\/j.clml.2016.01.006_bib1","first-page":"S1","article-title":"NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","volume":"9","author":"O'Brien","year":"2011","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2016.01.006_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/15680096113139990090","article-title":"Treatment of chronic myeloid leukemia elderly patients in the tyrosine kinase inhibitor era","volume":"13","author":"Russo","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2016.01.006_bib3","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, Chronic Myelogenous Leukemia, 2015, version 1. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed January 12, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib4","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A\u00a0randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.01.006_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.01.006_bib6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.01.006_bib7","unstructured":"Food and Drug Administration Approval for Dasatinib. National Cancer Institute, Updated July 2013. Available at: http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-dasatinib. Accessed August 3, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib8","unstructured":"Food and Drug Administration Approval for Nilotinib. National Cancer Institute, Updated July 2013. Available at: http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-nilotinib. Accessed August 3, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib9","unstructured":"Food and Drug Administration Approval for Bosutinib. National Cancer Institute, Updated July, 2013. Available at: http:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/fda-bosutinib. Accessed August 3, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib10","series-title":"ICLUSIG (ponatinib) tablets: full prescribing information","author":"Ariad Pharmaceuticals","year":"2013"},{"key":"10.1016\/j.clml.2016.01.006_bib11","series-title":"ICLUSIG (ponatinib) tablets: full prescribing information","author":"Ariad Pharmaceuticals","year":"2014"},{"key":"10.1016\/j.clml.2016.01.006_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.01.006_bib13","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2217\/fon.15.119","article-title":"Should vascular effects of newer treatments be addressed more completely?","volume":"11","author":"Yang","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2016.01.006_bib14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.01.006_bib15","unstructured":"Saglio G, Hochhaus A, Hughes TP, et\u00a0al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Oral Presentation at American Society of Hematology Annual Meeting and Exposition, December 7-10, 2013, New Orleans, LA, 2013."},{"key":"10.1016\/j.clml.2016.01.006_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.01.006_bib17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl","key":"10.1016\/j.clml.2016.01.006_bib18","article-title":"Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON). Presented at the 2015 ASCO Annual Meeting","volume":"33","author":"Talpaz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.006_bib19","first-page":"1","article-title":"Major arterial events in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a meta-analysis","author":"Chai-Adisaksopha","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.01.006_bib20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.006_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jss.2009.08.014","article-title":"Predictors of axillary lymph node involvement in women with T3 breast cancers: analysis of 1988-2003 SEER data","volume":"161","author":"Fields","year":"2010","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.clml.2016.01.006_bib22","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2002.11.136","article-title":"Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer","volume":"20","author":"Burkhardt","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.006_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1019096030306","article-title":"Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer","volume":"2","author":"Penberthy","year":"1999","journal-title":"Health Care Manag Sci"},{"key":"10.1016\/j.clml.2016.01.006_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2008.08.034","article-title":"Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data","volume":"7","author":"Lang","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2016.01.006_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clml.2016.01.006_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"Supp 2","key":"10.1016\/j.clml.2016.01.006_bib27","first-page":"953","article-title":"Alteration of platelet function in patients with chronic myeloid leukemia","volume":"7","author":"Popov","year":"2009","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.clml.2016.01.006_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/MBC.0b013e328365776f","article-title":"Assessment of changes in membrane properties of platelets from patients with chronic myeloid leukaemia in different stages of the disease","volume":"25","author":"Popov","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clml.2016.01.006_bib29","unstructured":"Arias E. National vital statistics reports: United States life tables, 2010. Available at: http:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr63\/nvsr63_07.pdf. Accessed November 2, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib30","series-title":"Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases","year":"2006"},{"key":"10.1016\/j.clml.2016.01.006_bib31","first-page":"e29","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2016.01.006_bib32","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/cncr.28106","article-title":"Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis","volume":"119","author":"Brunner","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2016.01.006_bib33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00002512-200421110-00004","article-title":"Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis","volume":"21","author":"Menzin","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clml.2016.01.006_bib34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.STR.28.7.1507","article-title":"Public health burden of stroke","volume":"28","author":"Sacco","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.clml.2016.01.006_bib35","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clml.2016.01.006_bib36","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1590\/S0066-782X2012005000109","article-title":"Imatinib attenuates myocardial fibrosis in association with inhibition of the PDGFRalpha activity","volume":"99","author":"Ma","year":"2012","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.clml.2016.01.006_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.0000202487.68969.f7","article-title":"Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats","volume":"47","author":"Schellings","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.clml.2016.01.006_bib38","first-page":"103","article-title":"Ensuring access to affordable drug coverage in Medicare","volume":"27","author":"Antos","year":"2005","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.clml.2016.01.006_bib39","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1200\/JOP.2012.000822","article-title":"Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"9","author":"Vander Velde","year":"2013","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2016.01.006_bib40","series-title":"Costs and use of oral anti-cancer medications among senior Medicare part d beneficiaries","author":"Kaisaeng","year":"2012"},{"key":"10.1016\/j.clml.2016.01.006_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2014.55.3107","article-title":"Receipt of chemotherapy among Medicare patients with cancer by type of supplemental insurance","volume":"33","author":"Warren","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.01.006_bib42","unstructured":"Howlader N, Noone AM, Krapcho M, et\u00a0al (eds). SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. Available at http:\/\/seer.cancer.gov\/csr\/1975_2010\/, based on November 2012 SEER data submission, posted to the SEER web site, April\u00a02013. Accessed August 3, 2015."},{"key":"10.1016\/j.clml.2016.01.006_bib43","first-page":"469","article-title":"Presenting phases of chronic myeloid leukaemia","volume":"19","author":"Ahmed","year":"2009","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"key":"10.1016\/j.clml.2016.01.006_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1756-0500-7-142","article-title":"Phase distribution of chronic myeloid leukemia in Bangladesh","volume":"7","author":"Mottalib","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.clml.2016.01.006_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML-Study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.01.006_bib46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A\u00a0review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"Schneeweiss","year":"2005","journal-title":"J\u00a0Clin Epidemiol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016000525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:21Z","timestamp":1761870441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016000525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S2152265016000525"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.01.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}